Nuvectis Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.8%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$1.02next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly25.1MTarget: Sufficient to fund operations for at least 12 months
Accumulated Deficit Quarterly105.7MTarget: Minimize through disciplined R&D spending
Quarterly Net Loss Quarterly6.1MTarget: Manage within projected clinical trial budgets
Watch Items
- NXP900 Phase 1b Monotherapy and Combination EnrollmentTrigger: Completion of patient enrollment in target cohortsAction: Initiate data analysis and prepare for clinical readouts
- Cash Runway and Capital RequirementsTrigger: Cash balance falling below $15 millionAction: Evaluate utilization of the remaining $60 million ATM facility or broader $150 million shelf registration
- NXP800 Phase 1b Ovarian Cancer and Cholangiocarcinoma ProgressTrigger: Release of updated safety and preliminary efficacy dataAction: Assess clinical signal to determine registrational path or strategic partnerships
Research as of 20 Jun 2026